Inactive Instrument

Oxford Immunotec Global PLC Stock price

Equities

OXFD

GB00BGFBB958

Dynamic Chart
Oxford Immunotec Announces Use of T-SPOT®Discovery SARS-CoV-2 Kit CI
Oxford Immunotec Global PLC will Change its Name to Oxford Immunotec Global Limited CI
Oxford Immunotec Global PLC Announces Board Changes CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from S&P Global BMI Index CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from NASDAQ Composite Index CI
PerkinElmer (UK) Holdings Limited completed the acquisition of Oxford Immunotec Global PLC. CI
Oxford Immunotec Global PLC's Equity Buyback announced on January 7, 2019, has expired. CI
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection CI
Oxford Immunotec Global : Plans to Market T Cell Immune Response Measurement Kit to COVID-19 in South Korea MT
Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea CI
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-Cov-2 Kit and Include New Panel to Detect T Cells Reactive to Endemic Coronaviruses CI
Oxford Immunotec Global : Teams With Valneva on COVID-19 Vaccine Candidate Testing MT
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study CI
Sector Update: Health Care Stocks Add to Early Rise, Supported by Biotech Companies MT
Sector Update: Modest Advance for Health Care Stocks Despite Larger Gains for Biotechnology Sector MT
More news
Managers TitleAgeSince
Chief Executive Officer 50 22-05-26
Members of the board TitleAgeSince
Director/Board Member 55 21-03-07
More insiders
Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Oxford Immunotec Global PLC - Nasdaq